Sign In
Last checked at 
19 Nov 2024 07:00
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF REGULATION (EU) NO 596/2014 WHICH IS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED ("MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
19 November 2024
Abingdon Health Plc
("Abingdon" or the "Company")
Annual General Meeting Statement
At today's Annual General Meeting of Abingdon (AIM:ABDX), a leading international lateral flow contract development and manufacturing organisation, Dr Chris Hand, the Chairman of Abingdon, will make the following statement:
"We are pleased to report that the Group, as enlarged by its recent acquisitions, and the establishment of its US presence in Madision, Wisconsin, USA, expects to see continued revenue growth. Although it is early in the year and there are therefore various meaningful new contracts still to be won, typically in the second half of the financial year, the Board remains confident of solid progress for FY2025."
Enquiries
Abingdon Health plc | www.abingdonhealth.com/investors/ | |
Chris Yates, Chief Executive Officer | Via Walbrook PR | |
Chris Hand, Executive Chairman | ||
Zeus (Sole Broker and Nominated Adviser) | Tel: +44 (0) 20 3829 5000 | |
Chris Fielding / Alexandra Campbell-Harris (Corporate Finance) | ||
Fraser Marshall (Corporate Broking) | ||
Walbrook PR (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com | |
Paul McManus / Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 | |
Phillip Marriage | +44 (0)7867 984 082 | |
The person responsible for arranging the release of this announcement on behalf of the Company is Chris Yates, Chief Executive Officer of the Company.
About Abingdon Health plc
Abingdon Health is a leading med-tech contract service provider offering its services to an international customer base.
The Group's CDMO division offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health's CDMO division has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine and large-scale manufacturing; from "idea to commercial success".
Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Our consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external, management reviews and presentations, training and mentoring.
Abingdon Health's Abingdon Simply Test range of self-tests is an e-commerce platform that offers a range of self-tests to empowers consumers to manage their own health and wellbeing. The Abingdon Simply Test e-commerce site offers consumers a range of information to support them in making informed decisions on the tests available. In addition, the site provides Abingdon's contract services customers with a potential route to market for self-tests. The Abingdon Simply Test range is also sold through international distributors and through other channels in the UK and Ireland, such as pharmacy chains.
Founded in 2008, Abingdon Health is headquartered in York, England.
For more information visit: www.abingdonhealth.com
Follow the stocks
